Monte Rosa Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Monte Rosa Therapeutics, Inc. carries a market capitalization of 1.17B, placing it among publicly traded companies globally. Its enterprise value stands at 1.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.17B |
| Enterprise Value | 1.48B |
Share Statistics
Monte Rosa Therapeutics, Inc. currently has 85.23M shares outstanding.
| Shares Outstanding | 85.23M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Monte Rosa Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 23.63. The price-to-sales ratio is 62.52, and the price-to-book ratio stands at 4.23.
| PE Ratio | 23.63 |
| PS Ratio | 62.52 |
| PB Ratio | 4.23 |
| P/TBV Ratio | 4.23 |
| P/FCF Ratio | -111.84 |
| P/OCF Ratio | -74.62 |
Enterprise Valuation
On an enterprise value basis, Monte Rosa Therapeutics, Inc. trades at an EV/EBITDA multiple of 6.34 and an EV/FCF ratio of 0.70. The EV/Sales ratio of 51.50 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.55 provides insight into valuation relative to core operating earnings.
| EV / Sales | 51.50 |
| EV / EBITDA | 6.34 |
| EV / EBIT | 12.55 |
| EV / FCF | 0.70 |
Financial Position
Monte Rosa Therapeutics, Inc. maintains a current ratio of 10.58, meaning it holds 10.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.58 |
| Quick Ratio | 10.49 |
| Debt / Equity | 7.80 |
| Debt / EBITDA | -0.22 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -42.66 |
| Return on Assets (ROA) | -30.67 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -2.86M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Monte Rosa Therapeutics, Inc.'s stock has gained approximately 181.87373% over the past 52 weeks. The 50-day moving average sits at 19.16, while the 200-day moving average is 18.52.
| Beta (5Y) | N/A |
| 52-Week Price Change | 181.87373% |
| 50-Day Moving Average | 19.16 |
| 200-Day Moving Average | 18.52 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Monte Rosa Therapeutics, Inc. generated 28.73M in revenue and converted that into -161.12M in net income, yielding earnings per share of -2.17. EBITDA reached -173.73M, while operating income came in at -181.85M.
| Revenue | 28.73M |
| Gross Profit | N/A |
| Operating Income | -181.85M |
| Pretax Income | -163.97M |
| Net Income | -161.12M |
| EBITDA | -173.73M |
| EBIT | -181.85M |
| Earnings Per Share (EPS) | -2.17 |
Balance Sheet
Monte Rosa Therapeutics, Inc. holds 621.10M in cash and equivalents against 37.99M in total debt, resulting in a net debt position of -90.10M. Total book value stands at 487.28M, with working capital of 571.75M providing operational flexibility.
| Cash & Cash Equivalents | 621.10M |
| Total Debt | 37.99M |
| Net Debt | -90.10M |
| Equity (Book Value) | 487.28M |
| Book Value Per Share | 5.72 |
| Working Capital | 571.75M |
Cash Flow
Monte Rosa Therapeutics, Inc. produced -24.07M in operating cash flow over the past twelve months. After subtracting -8.01M in capital expenditures, free cash flow totaled -32.08M - equivalent to -0.43 per share.
| Operating Cash Flow | -24.07M |
| Capital Expenditures | -8.01M |
| Free Cash Flow | -32.08M |
| FCF Per Share | -0.43 |
Margins
Monte Rosa Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -633.04 and net profit margin of -560.85 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -633.04 |
| Pretax Margin | -570.80 |
| Profit Margin | -560.85 |
| EBITDA Margin | -604.76 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -17.53 |
| FCF Yield | -0.89 |
Scores
Monte Rosa Therapeutics, Inc. posts an Altman Z-Score of 5.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.09 |